ClinicalTrials.gg
RecruitingNCT06411158TULIPUpdated Dec 31, 2025

Training for Urinary Leakage Improvement After Pregnancy

An interventional study of Interventionist-guided training and Home pelvic floor exercises guided by the leva® device in Urinary Incontinence and Delivery Complication, sponsored by NICHD Pelvic Floor Disorders Network. Recruiting at 7 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-31.

Sponsored by NICHD Pelvic Floor Disorders Network · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
216
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 293 studies in Urinary Incontinence with a site in United States — 33 open to participants now, 47 under way, 3 of them phase 3. Urinary Incontinence · United States.

Planned enrollment
62nd of 249
216 · median 75
Started
2024
with 16 others
No phase
144 of 293
21 open now
Primary completion
2027-05
later than 24 of 46 live
Registered
269th of 293
by date
Lead sponsor
9 of 293
NICHD Pelvic Floor Disorders Network

Among the 293 studies in Urinary Incontinence with a site in United States, this one is the 62nd largest by planned enrollment of the 249 interventional ones that give a count, is one of 17 that started in 2024, is one of 144 with no phase, reaches primary completion later than 24 of the 46 other live ones, and was the 269th registered.

Urinary Incontinence

988 studies on the registry are indexed under Urinary Incontinence; 184 are open to participants now.

Browse Urinary Incontinence studies →

Open to participants now

33 of the 293 studies in Urinary Incontinence with a site in United States are open now. Recruiting first, the newest first:

27 more — sign in →

All 33 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 113 Urinary Incontinence studies recruiting now, 63 (56%) set no upper age limit and 35 (31%) stop at 75 or younger; 15 take children under 18; 28 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 293 studies in Urinary Incontinence with a site in United States, or all of them as a file.
02

Study summary

This is a multi-center, randomized single-blind nonsurgical trial conducted in approximately 216 primiparous postpartum women at high risk for prolonged/sustained pelvic floor disorders with symptomatic, bothersome urinary incontinence (UI) amenable to nonsurgical treatment.

TULIP is a 3-Arm trial with two active interventions (Arms 1 and 2) and a Patient Education control arm (Arm 3). Arm 1 consists of pelvic floor muscle training (PFMT). Arm 2 uses a home biofeedback device (leva®).

The primary outcome will be assessed at 6 months postpartum by blinded outcomes assessors, and follow-up will continue until 12 months postpartum.

Read the detailed description

TULIP is a 3-Arm trial with two active interventions (Arms 1 and 2) and a Patient Education control arm (Arm 3). Arm 1 consists of pelvic floor muscle training (PFMT) sessions with a skilled interventionist. Arm 2 uses a home biofeedback device (leva®).

All groups will have access to basic education on stress urinary incontinence, overactive bladder, pelvic floor muscle function and continence mechanisms.

Arm 1 will consist of interventionist-guided training at baseline (approximately 8 weeks postpartum), followed by a Home Exercise Prescription (HEP), a second interventionist-guided training session (approximately 4 weeks later), and then continued HEP until 12 months postpartum. Home exercises will be encouraged using a PFDN research smartphone app, resources to help participants with home exercises and prompts for participants to confirm the number of exercise sets completed.

Arm 2 will consist of home pelvic floor exercises guided by the leva® device and its accompanying app/software for gradually increasing strength and duration of pelvic floor contractions. The Arm 2 exercise regimen begins at approximately 8 weeks postpartum and continues until 12 months postpartum. As in Arm 1, the PFDN research smartphone app resources to help participants with home exercises and prompts for participants to confirm the number of exercise sets completed.

Arm 3 participants will only be provided basic education materials. No specific prescription or verbal direction will be given regarding the suggested number and frequency of home pelvic floor muscle exercises.

The primary outcome is change in UI as measured by the ICIQ-SF, comparing scores from baseline to 6 months postpartum. The questionnaire will be sent to participants monthly from baseline through 12 months postpartum, and change through 12 months postpartum is a secondary outcome.

03

Conditions studied

  • Urinary Incontinence
  • Delivery Complication

Keywords

  • Urinary Incontinence
  • Pelvic Floor Disorders
  • Physical Therapy
  • Biofeedback
  • Anal Incontinence
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. ≥18yo primiparous patient s/p singleton vaginal delivery (>32 weeks), approximately 6wk postpartum
  2. At increased risk of sustained pelvic floor disorders, as defined by

    1. neonate ≥3.5kg, and/or
    2. operative delivery (i.e., forceps or vacuum-assisted vaginal delivery), and/or
    3. ≥2nd-degree perineal laceration
  3. Symptomatic, bothersome UI as defined by a score of ≥6 on the ICIQ-SF.

Exclusion criteria

Exclusion Criteria:

  1. Inability to complete study assessments or procedures, per clinician judgment, or not available for 6mo postpartum follow-up
  2. Stillbirth or significant maternal or neonatal illness
  3. Non-English or non-Spanish speaking
  4. Perineal wound breakdown or cloaca observed on exam
  5. Severe pain with assessments of PFM integrity and/or strength/function
  6. Already engaged (since delivery) in in-person physical therapy for strengthening of the pelvic floor
  7. Unwilling or unable to upload and use external smartphone app(s)
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
216 participants (estimated)

Study arms

  • Active comparator
    Interventionist-guided training

    Interventionist-guided training at baseline (i.e., approximately 8 weeks postpartum), followed by a Home Exercise Prescription (HEP), a second interventionist-guided training session approximately 4 weeks later, and then continued HEP. Two exercise sets per day are encouraged between baseline and 6 months postpartum (i.e., time of the primary outcome), followed by at least 3 times-per-week exercise sets until 12 months postpartum. Home exercises will be encouraged using a PFDN research smartphone app, resources to help participants with home exercises and prompts for participants to confirm the number of exercise sets completed.

    Other: Interventionist-guided training

  • Active comparator
    Home pelvic floor exercises guided by the leva® device

    Home pelvic floor exercises guided by the leva® device and its accompanying app/software for gradually increasing strength and duration of pelvic floor contractions. The PFDN research smartphone app will have weekly queries of whether exercises were completed.

    Device: Home pelvic floor exercises guided by the leva® device

  • Other
    Education

    Education will be provided on pelvic floor muscle function and continence mechanisms. No specific prescription or verbal direction will be given regarding the suggested number and frequency of home pelvic floor muscle exercises.

    Other: Education

Interventions

  • OtherInterventionist-guided training

    Interventionist-guided training at baseline (i.e., approximately 6 weeks postpartum), followed by a Home Exercise Prescription (HEP), a second interventionist-guided training session approximately 4 weeks later, and then continued HEP. Two exercise sets per day are encouraged between baseline and 6 months postpartum (i.e., time of the primary outcome), followed by at least 3 times-per-week exercise sets until 12 months postpartum. Home exercises will be encouraged using a PFDN research smartphone app, resources to help participants with home exercises and prompts for participants to confirm the number of exercise sets completed.

  • DeviceHome pelvic floor exercises guided by the leva® device

    Home pelvic floor exercises guided by the leva® device and its accompanying app/software for gradually increasing strength and duration of pelvic floor contractions. Between baseline and 6 months postpartum, twice-daily exercise sets will be encouraged, followed by at least 3 times-per-week exercises from 6 to 12 months postpartum. As in Arm 1, the PFDN research smartphone app, resources to help participants with home exercises and prompts for participants to confirm the number of exercise sets completed.

  • OtherEducation

    Education will be provided on pelvic floor muscle function and continence mechanisms. No specific prescription or verbal direction will be given regarding the suggested number and frequency of home pelvic floor muscle exercises.

06

What researchers measure

Primary outcomes

  1. Change in urinary incontinence measure by the ICIQ-SF

    The primary outcome is change in urinary incontinence (UI) as measured by the International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF), comparing scores from baseline to 6 months postpartum. This instrument consists of 3 scorable questions measuring frequency of leakage, volume of leakage, and associated bother with leakage. ICIQ-SF scores range from 0 (no leakage or bother) to 21 (worst leakage, most bothersome).

    Time frame: From baseline to 6 months postpartum

Secondary outcomes

  1. Change in Lower Urinary Tract Dysfunction Research Network Symptom Index (LURN-SI-10) score

    Lower Urinary Tract Dysfunction Research Network Symptom Index (LURN-SI-10) is designed to address a broader spectrum of lower urinary tract symptoms, particularly incontinence, bladder pain, and post-micturition symptoms. The LURN-SI-10 score ranges from 0 (least severe) to 38 (most severe).

    Time frame: From baseline to 6 months and 12 months postpartum

  2. Patient Global Impression of Improvement (PGI-I) score

    Patient Global Impression of Improvement (PGI-I) captures a participant's perceived improvement from baseline, defined as (1) = very much better, (2) = much better, (3) = a little better, (4) = no change, (5) = a little worse, (6) much worse, (7) very much worse.

    Time frame: At 6 months and 12 months postpartum

  3. Change in St. Mark's score

    The St. Mark's questionnaire is used to assess anal incontinence symptom severity. St. Mark's Score, ranges from 0 (perfect fecal continence) to 24 (total fecal incontinence).

    Time frame: From baseline to 6 months and 12 months postpartum

  4. Female Sexual Function Index (FSFI) score

    Sexual function will be assessed using the Female Sexual Function Index (FSFI), which uses 19 questions to measure 6 domains: desire, arousal, lubrication, orgasm, satisfaction, and pain. Female Sexual Function Index scores range from 2.0 (lowest sexual function) to 36.0 (high sexual function).

    Time frame: At 6 months and 12 months postpartum

  5. Change in urinary incontinence measure by the ICIQ-SF

    The International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF) consists of 3 scorable questions measuring frequency of leakage, volume of leakage, and associated bother with leakage. ICIQ-SF scores range from 0 (no leakage or bother) to 21 (worst leakage, most bothersome).

    Time frame: From baseline to 12 months postpartum

07

Study locations

7 of 7 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Study data will be made available through DASH

Time frame: Plan to submit full study dataset before the end of the award period.

Access criteria: Access is managed by DASH.

Data sharing details ↗ · dash.nichd.nih.gov

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for May 2027, 30 months after the start.

Of 303 non-industry interventional studies with no phase under Urinary Incontinence, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 37. This study's planned 30 months is above that.

Counting every sponsor, half of 366 studies reached it within 15 months; a quarter within 7 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
May 3, 2024
First posted
May 13, 2024
StartActual
Nov 12, 2024
Primary completionEst.
May 12, 2027
CompletionEst.
Nov 12, 2027
Last update
Dec 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06411158
Lead sponsor
NICHD Pelvic Floor Disorders Network
Responsible party
Sponsor
First posted
May 13, 2024
Start date
Nov 12, 2024
Primary completion
May 12, 2027 (estimated)
Completion
Nov 12, 2027 (estimated)
Last update
Dec 31, 2025

Study contacts

David Rahn, MD
principal investigator · UTSW
Marie Gantz, PhD
principal investigator · RTI International

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion